DJIA 17,164.95 -251.90 -1.45%
NASDAQ 4,635.24 -48.17 -1.03%
S&P 500 1,994.99 -26.26 -1.30%
market minute promo

5.25 -0.10 (-1.87%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

OREX $5.25 -1.87%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $5.33
Previous Close $5.35
Daily Range $5.23 - $5.41
52-Week Range $3.11 - $7.82
Market Cap $646.6M
P/E Ratio -9.91
Dividend (Yield) $0.00 (0.0%)
Volume 1,113,617
Average Daily Volume 2,838,553
Current FY EPS -$0.31





Orexigen Therapeutics, Inc. (OREX) Description

A biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system, disorders, with an initial focus on obesity. Website:

News & Commentary

Newly Approved Weight Loss Method Works by Tricking Your Brain

What's the best way to lose weight? One company thinks it's simple: don't get hungry.

Gallup Says Obesity Rates Climb Again - Can Anti-Obesity Companies Cash In?

Arena - Flat Scripts Is Not A Good Start To 2015

Contrave Scripts Continue Increases For Orexigen

Arena's Belviq Prescriptions Fall: More Publicity Is Needed

Novo Nordisk Receives Positive Opinion In Europe On Obesity Treatment

Orexigen Scripts Continue Impressive Track

Forget Pills! Could This Device Put an End to Obesity in America?

We've witnessed three oral anti-obesity meds approved since mid-2012, but this newly approved device could be a game-changer.

5 Obesity Stocks Investors Are Watching

A Deeper Look At Arena's Belviq Pricing

See More OREX News...

OREX's Top Competitors

OREX $5.25 (-1.87%)
Current stock: OREX
AMGN $152.26 (-2.63%)
Current stock: AMGN
GILD $104.83 (0.62%)
Current stock: GILD
BIIB $389.16 (10.17%)
Current stock: BIIB